Sculptor Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Sculptor Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-580,776	Closed	-$107M	–	1172
2021 Q2	$107M	Sell	580,776 -1,441,598	-71%	-$247M	0.78%	34
2021 Q1	$309M	Buy	2,022,374 +1,688,169	+505%	+$261M	2.53%	6
2020 Q4	$52.2M	Buy	+334,205	New	+$42.9M	0.23%	50
2015 Q1	–	Sell	-6,772	Closed	-$1.25M	–	796
2014 Q4	$1.25M	Sell	6,772 -2,200	-25%	-$408K	﹤0.01%	610
2014 Q3	$1.49M	Sell	8,972 -900	-9%	-$148K	﹤0.01%	637
2014 Q2	$1.54M	Sell	9,872 -3,500	-26%	-$553K	﹤0.01%	627
2014 Q1	$2.03M	Buy	+13,372	New	+$2.13M	0.01%	603

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Sculptor Capital's ALXN Position: Q3 2021 in Review

Sculptor Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 580,776 shares — an estimated $107M sold.

Sculptor Capital first reported a position in ALXN in Q1 2014 and held it in 7 quarters. The position peaked at $309M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Sculptor Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Sculptor Capital sold 580,776 Alexion Pharmaceuticals shares in Q3 2021, an estimated $107M.
Sculptor Capital first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 7 quarters.
Sculptor Capital's Alexion Pharmaceuticals position peaked at $309M in Q1 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Sculptor Capital's 13F filing for Q3 2021, filed 12 Nov 2021.